Financial Data and Key Metrics Changes - AEye ended 2025 with nearly $87 million in cash, providing funding well into 2028 [4] - GAAP net loss for Q4 was $7.3 million, or $0.17 per share, an improvement from a loss of $9.3 million, or $0.30 per share in Q3 [17] - Non-GAAP net loss for Q4 was $6.8 million, or $0.15 per share, compared to a loss of $5.4 million, or $0.17 per share in the prior quarter [18] - Cash burn increased to $7.5 million in Q4 from $6.4 million in Q3, primarily due to increased engineering costs and other expenses [18][19] Business Line Data and Key Metrics Changes - AEye shipped the highest number of Apollo units in its history during Q4, indicating increased customer readiness [16] - Active customer count grew from 12 to 16, with active engagements up over 40% and active quotes up more than 30% quarter-over-quarter [16] - The company launched multiple products, including Optis and Stratos, enhancing its competitive position in the lidar market [5][10] Market Data and Key Metrics Changes - AEye is seeing broader market interest, including new RFIs and strategic partnerships, particularly in autonomous trucking and defense sectors [4][8] - The Physical AI market is estimated to represent a $5 billion market today, with potential growth to $1 trillion by 2035 [10] - AEye received multiple new RFQs and entered a strategic partnership with a distributor to unlock opportunities outside the U.S. [8] Company Strategy and Development Direction - AEye aims to convert customer engagements into deployments and build a durable revenue ramp [23] - The company is focused on maintaining a capital-light operating model while investing in sales and marketing to support growth [19][20] - AEye's partnership with NVIDIA is deepening, enhancing its commitment to quality and safety in the automotive sector [29][52] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growing customer base and engagement activity, indicating a strong foundation for future growth [4][23] - The company expects 2026 to show increasing momentum towards a revenue generation inflection point as technical engagements translate into volume commitments [20][22] - Management highlighted the importance of flexibility and scalability in their technology to meet diverse customer needs [21][22] Other Important Information - AEye's supply chain is globally diversified, providing flexibility to mitigate geopolitical risks [12] - The company has secured dedicated manufacturing capacity of 60,000 Apollo units annually through its partnership with LITEON [11] Q&A Session Summary Question: Can you talk about the jump in your customer base this quarter? - Management noted that the increase to 16 active customers reflects growing activity and business opportunities, particularly in the non-automotive pipeline [25][26] Question: Any new developments on the NVIDIA partnership? - The relationship with NVIDIA is deepening, with AEye showcasing Apollo integrated with NVIDIA's latest autonomous platform at CES [28][29] Question: What kind of CapEx range are you modeling for 2026? - Expected CapEx for 2026 is relatively low, likely under $1 million, due to the capital-light business model [41][42] Question: Can you provide a percentage split between hardware and software revenue? - Currently, revenue is predominantly hardware-based, but there is a shift towards software with opportunities for customization and upselling [43][45] Question: What applications does the partnership with NVIDIA's Helios ecosystem address? - The partnership focuses on enhancing robustness and safety in the automotive space, building on previous collaborations [51][52] Question: Will the $30 million global transport win contribute revenue in 2026? - Some revenue is expected in 2026, but significant contributions are anticipated in 2027 as the customer validates the technology [53][56] Question: Were any of the new customers related to Optis and Stratos? - Most sales in 2025 were driven by Apollo and Optis, with Stratos expected to open new opportunities moving forward [57][62]

Financial Data and Key Metrics Changes - Babcock & Wilcox reported consolidated revenues of $587.7 million for 2025, a modest increase from $581 million in 2024 [24] - Adjusted EBITDA for the fourth quarter was 53% higher compared to the fourth quarter of 2024, with operating income up 373% year-over-year [20] - The company achieved a significant reduction in net debt, ending 2025 with $119.7 million, down from $337 million at the end of 2024 [22][29] Business Line Data and Key Metrics Changes - Parts and services revenue grew by over 17% in 2025, driven by increased coal generation usage and growing baseload demand in North America [9][25] - The backlog for continuing operations rose to $2.8 billion, a 470% increase compared to the end of 2024 [19] Market Data and Key Metrics Changes - Existing coal plants in the US have been operating at less than 50% capacity, with utilities reconditioning these plants to meet rising power demand [8] - The company’s pipeline of opportunities exceeded $12 billion, growing by roughly 20% in 2025 [16] Company Strategy and Development Direction - Babcock & Wilcox is focused on expanding into power generation for AI data centers, with a robust pipeline of project opportunities [31] - The company announced a full approval for a $2.4 billion project with Base Electron, aimed at delivering 1.2GW of electricity [11][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting construction timelines for the Base Electron project, with site visits and manufacturing processes already underway [42][44] - The company anticipates strong financial performance throughout 2026, driven by global demand for baseload electrical generation [32] Other Important Information - The company is celebrating its 160th anniversary, reflecting on its historical milestones and innovations in power generation technologies [34][35] - Babcock & Wilcox is actively working with the Boilermaker Union to prepare the labor force needed for upcoming projects [13] Q&A Session Summary Question: Can you discuss the dynamics of the Base Electron project and its timeline? - Management explained the transition from a limited notice to a full notice to proceed, highlighting the variability in project scope and final amounts [40][41] Question: What is the visibility into the guidance increase and expected contributions from the power generation project? - Management indicated that the guidance increase includes contributions from the power project, but specifics will depend on cost recognition as work progresses [46][47] Question: Can you provide an update on the coal to gas project and the pipeline for similar opportunities? - Management confirmed that the coal to gas project is on schedule, with additional conversion projects being discussed due to rising natural gas prices [54][56] Question: How mature are the discussions on other projects compared to Base Electron? - Management noted that discussions are ongoing and some projects are in advanced stages, but specific timelines cannot be disclosed yet [80][82] Question: How has the announcement of the Applied contract impacted market interest? - Management reported significant inbound interest from various market participants following the announcement, indicating a positive market response [85][88]

Financial Data and Key Metrics Changes - Microvast achieved record annual revenue of $427.5 million in 2025, a 12.6% increase from $379.8 million in 2024 [6][13] - The annual gross margin was 28.6%, down from 31.5% in 2024, primarily due to a $32.5 million inventory impairment charge [6][14] - GAAP net loss for the year was $29.2 million, an improvement from a net loss of $195.5 million in 2024 [6][16] - Non-GAAP adjusted net profit was $13 million, compared to a non-GAAP adjusted net loss of $84.6 million in 2024 [6][17] - Non-GAAP adjusted EBITDA improved to $44.7 million from -$44.8 million in 2024 [6][17] Business Line Data and Key Metrics Changes - The company recorded a 25% revenue growth at an industry-leading gross margin, indicating strong customer demand for Microvast technology [7] - The Huzhou phase 3.2 expansion is expected to add up to 2 GWh of annual production capacity, critical for future growth [9][10] Market Data and Key Metrics Changes - U.S. revenue grew 173% year-over-year to $39.3 million, contributing 9% of total revenue [18] - EMEA revenue increased by 13% year-over-year to $211.9 million, accounting for approximately half of total revenue [18] - Asia Pacific revenue slightly declined by 1% to $176.3 million, reflecting challenges in the regulatory landscape in South Korea [19] Company Strategy and Development Direction - The company aims to focus on high-margin deliveries and expand its portfolio with specialized products and services [22] - The strategy is built on three pillars: innovate, expand, and capture, with a focus on synchronizing production increases with customer demand [22][24] - The Huzhou phase 3.2 expansion is a primary operational catalyst for 2026, with plans for serial production [24][25] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about continued revenue growth while navigating evolving tariff structures and geopolitical dynamics [22] - The company is committed to achieving production ramp-up milestones and protecting margins despite market volatility [25] - Management highlighted the resilience shown in 2025, achieving record revenue and a significant shift toward profitability [26] Other Important Information - The company generated a net positive operating cash flow of $75.9 million, a significant improvement from $2.8 million in 2024 [19] - Total cash equivalents and restricted cash increased to $169.2 million by year-end [21] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session.

Summary of PTC Investor Update Conference Call Company Overview - **Company**: PTC (NasdaqGS:PTC) - **Event**: Investor Update Conference Call - **Date**: March 16, 2026 Key Points Divestiture of Kepware and ThingWorx - PTC has completed the divestiture of Kepware and ThingWorx, focusing on its intelligent product lifecycle vision [4] - Transaction proceeds from the divestiture were $523 million, slightly below the previous estimate of $525 million due to working capital and indebtedness adjustments [4] - Divestiture-related costs are now expected to be approximately $40 million, an increase of $5 million from the previous estimate [5] - Cash taxes related to the transaction are now expected to be approximately $110 million, down from the previous estimate of $125 million [5] - Estimated net after-tax transaction proceeds are now $375 million, which is $10 million higher than the previous estimate of $365 million [5] Financial Guidance Post-Divestiture - Post-divestiture free cash flow guidance for fiscal 2026 is now $850 million, an increase of $10 million from the previous estimate of $840 million [6] - Cash inflows from the transition services agreement with TPG Inc. are expected to offset the absence of free cash flow from Kepware and ThingWorx [6] - For fiscal 2027, a free cash flow headwind of $70 million is anticipated, up from the previous estimate of less than $50 million [6] Revenue and Earnings Guidance - PTC is no longer including Kepware and ThingWorx in its guidance for Annual Recurring Revenue (ARR) [7] - Fiscal 2026 and Q2 2026 guidance for free cash flow, revenue, and non-GAAP EPS has been updated to reflect the divestiture [8] - A $464 million gain on the sale of Kepware and ThingWorx will be reflected in GAAP EPS, partially offset by the absence of earnings from these businesses post-close [8] Operating Expenses and Cash Taxes - Non-GAAP operating expenses are expected to grow at roughly half the rate of ARR [9] - Cash taxes for fiscal 2027 are estimated to be between $180 million and $220 million, as historical net operating losses have been consumed [9][10] - For fiscal 2026, cash taxes are expected to be between $130 million and $150 million, excluding those related to the divestiture [31] Share Buyback Strategy - PTC plans to use the majority of its free cash flow for share buybacks, with an expected range of $1.125 billion to $1.225 billion [16] Market Dynamics and Operational Efficiency - The organization has managed distractions from the divestiture process effectively, reaffirming guidance for Q2 [23] - PTC is focused on identifying areas for reallocation and efficiencies to maintain operational performance [19][27] Additional Insights - The divestiture is expected to provide a benefit of $70 million in FY 2026, which will not recur in the following year [19] - The company is committed to evaluating capital allocation strategies, including share buybacks, based on return on investment [29] This summary encapsulates the key discussions and financial metrics presented during the PTC Investor Update Conference Call, highlighting the company's strategic focus and financial outlook following the divestiture of Kepware and ThingWorx.

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $74.9 million, down from $120.8 million in Q4 2024, primarily due to the wind-down of migrant-related projects [17] - Adjusted EBITDA for Q4 2025 was a loss of $11.3 million compared to a profit of $1.1 million in Q4 2024 [18] - For the full year 2025, total revenue was $322.2 million, down from $616.6 million in 2024, with an adjusted EBITDA loss of $28.6 million compared to a profit of $60 million in 2024 [18][19] Business Line Data and Key Metrics Changes - Medical transportation services revenue increased to $50.2 million in Q4 2025 from $49.1 million in Q4 2024, driven by growth in both large and small U.S. markets [17][18] - Mobile Health revenue for Q4 2025 was $24.8 million, down from $71.8 million in Q4 2024, but non-migrant Mobile Health revenues increased by 47% [18][19] - SteadyMD generated over $8 million in revenue for the first time in Q4 2025, contributing $6.1 million to DocGo's results [7][8] Market Data and Key Metrics Changes - Medical transportation trips increased by 11%, healthcare in-home visits were up 113%, and telehealth and lab orders were up 50% compared to Q4 2024 [10] - The number of assigned lives in the care gap closure program increased by 12% sequentially, from 1.3 million to over 1.45 million [11] Company Strategy and Development Direction - The company is focused on integrating SteadyMD into its mobile health offerings and aims to consolidate provider networks by the end of Q2 2026 [8] - DocGo is exploring strategic alternatives to maximize shareholder value, engaging an investment bank for this process [15][28] - The company plans to reduce cash outlay in 2026 as early markets mature and become self-sustaining, with a goal of achieving profitability in the second half of 2026 [12][26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong demand for services and top-line growth, with an updated revenue guidance for 2026 of $290 million to $310 million [6][25] - The adjusted EBITDA loss is expected to improve to a range of $5 million to $10 million for 2026, down from previous guidance of $15 million to $25 million [26] - Management highlighted the importance of reducing SG&A expenses by 10%-15% through efficiency innovations [32] Other Important Information - The company incurred significant non-cash charges due to the write-down of intangible assets and goodwill, totaling $49.5 million and $22.6 million respectively in Q4 2025 [22] - Cash and cash equivalents at year-end were $68.3 million, down from $95.2 million, primarily due to the acquisition of SteadyMD and delays in collecting migrant-related accounts receivable [23][24] Q&A Session Summary Question: Can you provide details on the strategic alternatives process? - The company has engaged an investment bank to maximize shareholder value but cannot share further details at this time [28][29] Question: What are the drivers behind the increased 2026 guidance? - Increased volumes in Medical Transportation and additional upside from SteadyMD are the primary drivers for the revenue outlook increase [30][31] Question: Can you quantify free cash flow pressures in 2026? - The cash balance at year-end was lower than expected due to delays in collecting $20 million in migrant receivables, but the outlook for collectibility remains unchanged [36][39] Question: What is the status of the payer business and pipeline? - The company continues to see momentum in the payer business, with significant increases in visits and lives referred by payers [45][48] Question: How should we think about EBITDA cadence throughout the year? - Most of the adjusted EBITDA loss is expected in the first half of the year, with a turn to profitability in the second half [70][71]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $74.9 million, down from $120.8 million in Q4 2024, primarily due to the wind-down of migrant-related projects. Excluding these revenues, there was an 11% year-over-year increase in revenue for Q4 [24] - For the full year 2025, total revenue was $322.2 million compared to $616.6 million in 2024. Adjusted EBITDA for Q4 2025 was a loss of $11.3 million, compared to a gain of $1.1 million in Q4 2024 [27] - The adjusted gross margin for Q4 2025 was 32.5%, down from 33.5% in Q4 2024, with medical transportation segment margins improving to 32.8% from 30.1% [28] Business Line Data and Key Metrics Changes - Medical transportation services revenue increased to $50.2 million in Q4 2025 from $49.1 million in Q4 2024, driven by growth in both large and small U.S. markets [25] - Mobile Health revenue for Q4 2025 was $24.8 million, down from $71.8 million in Q4 2024, but non-migrant Mobile Health revenues increased by 47% [26] - SteadyMD generated over $8 million in revenue for the first time in Q4 2025, contributing $6.1 million to DocGo's results [10] Market Data and Key Metrics Changes - The number of patient interactions for SteadyMD exceeded 4 million in 2025, up from approximately 2.5 million in 2024, indicating strong growth in telehealth services [11] - The care gap closure program saw a 12% sequential gain in assigned lives, increasing from 1.3 million to over 1.45 million [16] Company Strategy and Development Direction - The company is focused on integrating SteadyMD into its mobile health offerings and aims to consolidate provider networks by the end of Q2 2026 [11] - DocGo is exploring strategic alternatives to maximize shareholder value, engaging an investment bank for this process [22] - The company plans to reduce cash outlay as early markets mature and become self-sustaining, targeting profitability in the second half of 2026 [17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about revenue growth driven by new customer expansions and improved hiring rates, raising 2026 revenue guidance to $290 million-$310 million [9] - The adjusted EBITDA loss is expected to improve to $5 million-$10 million in 2026, down from previous projections of $15 million-$25 million [39] - Management highlighted the importance of technology and automation in driving efficiency and reducing costs while maintaining high service levels [92] Other Important Information - The company incurred significant non-cash charges due to write-downs of intangible assets and goodwill, totaling $49.5 million and $22.6 million respectively in Q4 [34] - Cash and cash equivalents at year-end were $68.3 million, down from $95.2 million, primarily due to the acquisition of SteadyMD and delays in collecting migrant-related receivables [35][36] Q&A Session Summary Question: Can you provide details on the strategic alternatives process? - Management confirmed engagement with an investment bank to maximize shareholder value but could not disclose further details at this time [43] Question: What are the components driving the increased 2026 guidance? - The increase in guidance is primarily driven by improved volumes in the Medical Transportation segment and additional upside from SteadyMD [44][46] Question: Can you quantify free cash flow pressures in 2026? - Management indicated that cash balance was lower than expected due to delays in collecting $20 million in migrant receivables, but they expect to collect all of it [54][56] Question: What is the outlook for the payer business and potential new contracts? - Management noted ongoing momentum in the payer business and the potential for additional contracts, but current guidance is based on existing contracts and staffing [63][66] Question: How should we think about EBITDA cadence throughout 2026? - Most of the adjusted EBITDA loss is expected in the first half of the year, with a turnaround to profitability anticipated in the second half [90]

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $1.3 million, down from $3.1 million in Q4 2024, representing a decline of approximately 58.1% [23] - For the full year 2025, total revenue was $6.4 million, compared to $29.6 million in 2024, a decrease of about 78.4% [23] - Total operating costs and expenses for Q4 2025 were $14.8 million, up from $10.3 million in Q4 2024 [23] - For the full year 2025, total operating costs and expenses were $52.3 million, significantly reduced from $180 million in 2024 [23] - The net loss for Q4 2025 was $14.6 million, or $3.61 per share, compared to a net loss of $8.7 million, or $2.15 per share in Q4 2024 [25] - The net loss for the full year 2025 was $58.2 million, or $14.40 per share, down from a net loss of $153.1 million, or $38.26 per share in 2024 [25] - As of December 31, the company reported $109.4 million in cash equivalents, investments, and accounts receivable, with a cash runway expected into 2028 [26] Business Line Data and Key Metrics Changes - The company is advancing the FG-3246 program, a potential first-in-class antibody drug conjugate targeting CD46 in metastatic castration-resistant prostate cancer [4][5] - The FG-3246 program is expected to address a significant unmet need in late-stage prostate cancer, with an estimated total addressable market of over $5 billion annually in the U.S. [8] - Roxadustat is being developed for anemia associated with lower-risk myelodysplastic syndromes (MDS), with a significant opportunity due to the lack of oral treatments currently available [18][22] Market Data and Key Metrics Changes - Approximately 290,000 men are diagnosed with prostate cancer each year in the U.S., with about 65,000 drug-treatable patients with metastatic disease that has become castration-resistant [7] - The incidence of grade 3 or greater neutropenia was substantially reduced with the utilization of GCSF prophylaxis in ongoing trials [12] Company Strategy and Development Direction - The company aims to rebrand from FibroGen to Kyntra Bio to better reflect its focus on oncology and rare diseases [7] - The strategy includes advancing mid and late-stage assets and simplifying the capital structure to create value for shareholders [7] - The company is focused on developing FG-3246 and its companion FG-3180 program, with expected interim analysis from the phase 2 monotherapy trial in the second half of 2026 [27] Management's Comments on Operating Environment and Future Outlook - Management highlighted 2025 as a transformational year, emphasizing the importance of reducing fixed costs to maximize cash runway and invest in U.S. pipeline opportunities [26] - The company remains confident in its positioning to create meaningful therapeutic options for patients and significant value for shareholders [7] Other Important Information - The company has received orphan drug designation for roxadustat, which provides a minimum of 7 years of regulatory exclusivity [22] - The company is exploring opportunities to develop roxadustat internally or with a strategic partner [21] Q&A Session Summary Question: Imaging of CD46 opportunity and commercial potential - Management discussed the potential market for CD46 PET imaging agents and how they would fit into the treatment algorithm alongside existing PSMA agents [30][32] - The company anticipates that patients will need to show positive uptake of CD46 PET imaging to be prescribed FG-3246, similar to the requirements for PSMA agents [34] Question: SUV data and patient selection - Management acknowledged the provocative nature of the SUV data and its potential role in enriching patient selection for treatment [30][40] - The phase 2 trial is designed to define CD46 positivity, which may be based on SUV or other metrics [40] Question: Balance of patients in studies and recruitment - Management clarified that the phase 2 monotherapy trial will focus on patients who have progressed on only one prior ARPI, differentiating it from the IST [46] Question: Updates on roxadustat partnering efforts - Management stated that they are evaluating the opportunity to develop roxadustat internally or through collaboration but did not provide specific updates on the partnering process [49] Question: FDA feedback timeline for roxadustat - Management explained that the FDA indicated a feedback timeline of 60-90 days due to the nature of the protocol submission, which is currently being awaited [53]

Financial Data and Key Metrics Changes - Revenue increased to $34.9 million compared to $33.5 million in Q4 2024, reflecting strength in global licensing and Honey Birdette performance [18] - Operating expenses decreased to $32.2 million from $37.9 million in Q4 2024, primarily due to a 15% reduction in selling and administrative expenses [18] - Net income improved to $3.6 million, or 3 cents per share, from a net loss of $12.5 million, or 15 cents per share in Q4 2024 [19] - Adjusted EBITDA increased to $7.1 million, marking the fourth consecutive quarter of positive adjusted EBITDA, compared to an adjusted EBITDA loss of $100,000 in Q4 2024 [19] Business Line Data and Key Metrics Changes - Licensing generated over $46 million in revenue for fiscal year 2025, accounting for over 38% of total revenue at a 90% gross margin [12] - Honey Birdette sales grew 9% year-over-year, with full-price sales up 21% and gross product margin expanding to 77.8% [16] Market Data and Key Metrics Changes - The UK market led Honey Birdette growth with a 36% increase, while the US market saw a 21% increase [16] - Digital sales grew 7%, with the US market up 16% and average order value lifted 17% across all regions [16] Company Strategy and Development Direction - The company completed a strategic transformation focused on sustainable, profitable growth across four pillars: media and experiences, licensing, hospitality, and Honey Birdette [5][17] - The UTG China partnership is expected to close soon, providing $122 million in cash payments and nearly $52 million earmarked for debt reduction [21] - The company is focusing on high-margin, recurring revenue and brand-led growth, with a disciplined approach to licensing [5][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the brand's repositioning and its resonance with the target audience of 18- to 40-year-old males [28] - The company is optimistic about the potential for the hospitality segment, particularly with the relaunch of membership clubs [15][22] - Management highlighted the importance of the digital platform and subscription revenue model as key growth areas moving forward [21] Other Important Information - The company made two senior hires to drive growth: David Miller as President, Media and Brand, and Phillip Picardi as Chief Brand Officer and Editor-in-Chief [6] - The magazine relaunch is generating cultural momentum, with a major female musician as the newest cover star [22] Q&A Session Summary Question: Could you talk about the rebuild of your website and its objectives? - The primary goal is brand enhancement, followed by monetization, with a focus on creating a digital hub for content and subscription offerings [25] Question: Can you discuss the repositioning of the Playboy brand and its resonance with the target audience? - The brand is resonating well, with meaningful engagement in content production and a return to its roots as a modern guide for relationships and culture [28] Question: What is driving the strong performance of the Honey Birdette business? - The business is seeing success with full-price selling and has implemented a price increase without customer pushback, contributing to margin growth [35]

Financial Data and Key Metrics Changes - The company discussed its Q4 2025 financial results and emphasized the importance of addressing any remaining questions from investors [2][3] Business Line Data and Key Metrics Changes - The company highlighted its relationship with STL, a dominant label provider in the gift card industry, which is crucial for their software-based solutions [5][6] - The company is working on technological barriers related to scanner vendors, identifying them as a historic source of risk, and expects to resolve these issues in a few weeks [12][13] Market Data and Key Metrics Changes - The company mentioned the significant role of InComm and Blackhawk as the largest gift card networks in the U.S., which are influential in orchestrating card delivery to retailers [8] Company Strategy and Development Direction - The company is focusing on enhancing its leak detection solutions and is exploring partnerships to expand its market reach [26][28] - The company is also involved in the HolyGrail project, which aims to improve recycling processes and is expected to see critical mass in Belgium and Germany by Q2 and Q3 respectively [31][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in overcoming bottlenecks related to firmware updates and printer capacity, indicating a positive outlook for the gift card business [13][14] - The company is preparing for future commercialization of its solutions, particularly in the context of evolving industry requirements by 2030 [32] Other Important Information - The company is actively engaging with partners for its tax stamp authentication solution, which is being integrated as a security layer in existing offerings [33][34] Q&A Session Summary Question: Importance of STL in the supply chain - Management highlighted STL as a dominant label provider and a valuable R&D partner in the gift card industry [5][6] Question: Role of InComm and Blackhawk - Management confirmed that InComm and Blackhawk are the two largest gift card networks, crucial for the industry [8] Question: Status of firmware updates for scanners - Management indicated that they expect to resolve issues with scanner vendors in a few weeks and have built sufficient printer capacity [12][13] Question: Details on leak detection win - Management explained that the leak detection solution was developed for both web content and discrete media, with a recent win coming from a Fortune 100 company [23][24] Question: Commercialization of HolyGrail project - Management discussed the ongoing market demonstrations in Belgium and Germany, emphasizing the importance of achieving critical mass for commercialization [31][32] Question: Tax stamp authentication application - Management described the tax stamp solution as a layered security application developed through a partner [33][34]

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $1.3 million, down from $3.1 million in Q4 2024 [23] - For the full year 2025, total revenue was $6.4 million, compared to $29.6 million in 2024 [23] - Total operating costs and expenses for Q4 2025 were $14.8 million, up from $10.3 million in Q4 2024 [23] - Total operating costs and expenses for the full year 2025 were $52.3 million, down from $180 million in 2024 [23] - R&D expenses for Q4 2025 were $7.3 million, compared to $6.9 million in Q4 2024 [24] - R&D expenses for the full year 2025 were $23.5 million, down from $95.7 million in 2024 [24] - SG&A expenses for Q4 2025 were $7.3 million, compared to $8.3 million in Q4 2024 [24] - SG&A expenses for the full year 2025 were $27.7 million, down from $49.3 million in 2024 [24] - The net loss from continuing operations for Q4 2025 was $14.6 million, compared to a net loss of $8.7 million in Q4 2024 [25] - The net loss from continuing operations for the full year 2025 was $58.2 million, compared to a net loss of $153.1 million in 2024 [25] - As of December 31, 2025, the company reported $109.4 million in cash equivalents, investments, and accounts receivable, with a cash runway expected into 2028 [26] Business Line Data and Key Metrics Changes - The company is advancing the FG-3246 program, a potential first-in-class antibody drug conjugate targeting CD46 in metastatic castration-resistant prostate cancer [4][5] - The FG-3246 program is expected to address a significant unmet need in late-stage prostate cancer, with an estimated total addressable market of over $5 billion annually in the U.S. [7][8] - Roxadustat is being developed for anemia associated with lower-risk myelodysplastic syndromes (MDS), with a significant opportunity due to the lack of oral treatments currently available [18][22] Market Data and Key Metrics Changes - Approximately 290,000 men are diagnosed with prostate cancer each year in the U.S., with about 65,000 drug-treatable patients with metastatic disease [7] - Current treatments for anemia associated with lower-risk MDS are effective in less than 50% of patients, highlighting the need for new therapies [18] Company Strategy and Development Direction - The company aims to rebrand from FibroGen to Kyntra Bio to better reflect its focus on oncology and rare diseases [7] - The strategy includes advancing mid and late-stage assets and simplifying the capital structure to create value for shareholders [7] - The company plans to initiate a phase III trial for roxadustat in the second half of 2026 [21][27] Management's Comments on Operating Environment and Future Outlook - Management highlighted 2025 as a transformational year, emphasizing the importance of reducing fixed costs to maximize cash runway [26] - The company remains confident in its clinical programs and the potential for FG-3246 and FG-3180 to provide meaningful therapeutic options [7][27] Other Important Information - The company has received orphan drug designation for roxadustat, which provides a minimum of seven years of regulatory exclusivity [22] - The company is actively enrolling patients for the FG-3246 phase II trial and expects interim results in the second half of 2026 [15][27] Q&A Session Summary Question: Imaging of CD46 opportunity and commercial potential - Management discussed the positioning of CD46 PET imaging agents in relation to existing PSMA agents and the anticipated commercial opportunity [30][32] Question: SUV data and patient selection - Management addressed the correlation between SUV data and patient selection, noting the need to define CD46 positivity metrics in the phase II trial [30][40] Question: Balance of patients in studies - Management clarified that the phase II monotherapy trial will focus on patients who have progressed on one prior ARPI, differentiating from the IST [46] Question: Updates on roxadustat partnering efforts - Management indicated ongoing evaluations for internal development versus potential collaborations for roxadustat but did not provide specific updates [49] Question: Delay in FDA feedback for roxadustat - Management explained the expected timeline for FDA feedback on the IND submission, indicating a 60-90 day period for response [53][54]